Compare Novavax Inc (NVAX) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Under Armour Inc Class A — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Under Armour Inc Class A trades at $4.78 (market cap $2.07B). The key difference: Novavax Inc and Under Armour Inc Class A are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Under Armour Inc Class A for 18 Days on average.
| NVAX | UA | |
|---|---|---|
Market Cap | $1.82B | $2.07B |
Volume | 6,198,505 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.75 | $7.88 |
52-Week Low | $6.22 | $3.96 |
Typical Hold Time | 59 Days | 18 Days |
Enterprise Value | $1.39B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Under Armour (UA) trades at $4.74, up 0.85% with a bullish technical signal despite mixed fundamentals. The company reported Q2 2026 EPS beat but faces revenue declines and negative profitability margins. Cash flow remains negative with $362M outflow in 2025, while analyst consensus shows divided opinions with 40% buy ratings amid ongoing operational challenges.
Outlook remains challenging with revenue guidance cuts and persistent net losses. Investment opportunity exists in potential turnaround execution, but risks include competitive pressures and weak consumer demand. The stock's low P/S ratio of 0.41 offers value potential if management can stabilize operations and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
